F. Hoffmann-La Roche Ltd: Roche reports solid results in 2020
F. Hoffmann-La Roche Ltd: Roche reports solid results in 2020 Group sales increase 1% 1 at constant exchange rates (CER); 5% decline in Swiss francs, as a result of continued appreciation of the Swiss franc against most currencies Pharmaceuticals Division sales decline 2%; continued strong sales growth of newly launched medicines (+32% 2, including Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla) largely offsets the impact of competition from biosimilars (CHF -5.1 billion at CER 3), but not the additional COVID-19-related impact from missed medical appointments Diagnostics Division sales gr...